Exhibit G

- - -

IN RE: PELVIC MESH/GYNECARE LITIGATION	:SUPERIOR COURT OF NEW JERSEY :LAW DIVISION - ATLANTIC COUNTY : :MASTER CASE 6341-10 : :CASE NO. 291 CT

CONFIDENTIAL-SUBJECT TO STIPULATION AND ORDER OF CONFIDENTIALITY

- - -

September 13, 2012

- - -

Volume II of the transcript of the Deposition of CHARLOTTE OWENS, M.D., called for Videotaped Examination in the above-captioned matter, said deposition taken pursuant to Superior Court Rules of Practice and Procedure, by and before JoRita B. Meyer, a Certified Realtime Reporter, Registered Merit Reporter, and Certified Court Reporter for the State of Georgia, at the offices of Troutman Sanders, 600 Peachtree Street Northeast, Atlanta, Georgia, commencing at 9:11 a.m.

- - -

GOLKOW TECHNOLOGIES, INC.
877.370.3377 ph|917.951.5672 fax
deps@golkow.com

A. Correct.

Q. And it says the potential effect of that is damage to the cannula and the potential hazard what could occur would be tissue damage, correct?

A. Correct.

Q. And the potential harm that could result here is described as bleeding, correct?

A. Correct.

Q. And you understood that through your review of this -- rephrase.

And you understood that it was required that you capture all of the different failure modes, all the things that could go wrong in the procedure, even if the doctor was properly trained and following the proper procedure, and the effects of those failure modes, the hazards that could occur, and the resulting harms, and you were supposed to capture all of them, correct?

A. Yes, all that we could conceive of, yes.

Q. Now, one of the things that could happen is during the passage of the guides, is the pudendal nerve could be injured, correct?

specifically mentioned in the document.

BY MR. SLATER:

Q. And therefore, none of them are specifically scored, correct?

A. They would have been included in things other than the terms that you mentioned.

Q. As the document appears and as it was specifically and carefully written by quality engineering, with your approval, those items do not appear and are not specifically scored, correct?

A. Those items are not specifically mentioned, no.

Q. All right. Now let's look at the dFMEA, which is Exhibit 629. You understood the purpose of the dFMEA, correct?

A. Yes.

Q. That's the Design Failure Modes and Effects Analysis, correct?

A. Yes.

Q. And what was the purpose of this analysis?

A. To review the potential risk associated with the design of the product.

Q. And when you say "associated with the

design of the product," that means that when the product is in a woman's body and the product was manufactured completely consistent with the specifications, these are the things that could go wrong and harm a patient, correct?

A. Correct.

Q. Let's look now at this dFMEA, and let's look at page -- looking at the Bates number 03573, the actual chart and grid.

And it indicates that you were one of the individuals who provided input as medical director, correct?

A. Yes.

Q. And again, as with the aFMEA, you had to sign off on the dFMEA in order for this gate to be surpassed so the product could move closer to Product Release Authorization and to be marketed to be put in women's bodies, correct?

A. Correct.

Q. And what this does is, in the chart, is the different components of the PROLIFT kit are each evaluated in terms of what harms they could cause if they were to fail, correct?